



A leading diagnostics company driven to improve patient care and outcomes.

## MISSION

Our mission is to transform patient care and improve outcomes through personalized diagnostics that are timely, accessible, and address immediate clinical needs.

## VISION

We envision a world where patient diseases are conquered with the guidance of personalized diagnostics.

## WHAT WE DO

Innovating with multiple life sciences approaches and technologies, including genomics, proteomics, and radiomics, combined with artificial intelligence (AI), we discover, develop, and commercialize diagnostic tests, all in the pursuit of improving patient care and outcomes.

FOUNDED	2006   Colorado
COMPANY HEADQUARTERS	Louisville, CO
LABORATORY LOCATIONS	Louisville, CO De Soto, KS
LABORATORY CERTIFICATIONS	New York State CLEP-approved CAP-accredited, CLIA-certified ISO 13485-certified
EMPLOYEES	~300 as of 1Q2025
REVENUES	\$71.3M FY2024
INTELLECTUAL PROPERTY	100+ patents 20+ protected trademarks 300+ clinical data publications
ACTIVE CLINICAL STUDIES	ALTITUDE, CLARIFY, INSIGHT
IPO	October 2020   Nasdaq: BDSX
SECTOR	Life Sciences Tools & Diagnostics (LSTDx)

## Biodesix has two business lines:

### Lung Diagnostic Tests

Supporting clinical decisions to expedite personalized care and improve outcomes for patients with lung disease.



### Development Services

Enabling the world's leading biopharmaceutical, life sciences, and academic research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics.



## Workplace Culture & Community

At Biodesix, our team members are encouraged to put their fingerprints on all that we do in the pursuit of our mission and vision. To encourage high-performance and a growth mindset, we created our Operating Principles: **Team, Impact, Excellence**. We also have a philanthropic program, **Biodesix Gives Back**, which includes 10 hours of paid time off to volunteer at an organization of the team member's choice. Based on comprehensive, anonymous employee engagement surveys in 2024 and 2025, Biodesix was recognized with exclusive national Best Workplaces awards from *Inc. Magazine* and the *Denver Post*. These rankings benchmark the employee responses across industry sectors; winners are decided within comparable-sized company cohorts.



## LUNG CANCER FACTS



Each year, there are almost as many Americans that die from lung cancer as these 3 cancers combined: breast, colorectal, and prostate cancers.



**Only 27% of lung cancers** are diagnosed at an early stage of the disease

# 7x

There's an **7x greater survival** when lung cancer can be diagnosed at an early stage, such as lung nodule presentation



80% of lung nodules of 8-30mm in size have **intermediate risk** for cancer and these patients are frequently over- and under-treated

**Sources** 1. American Cancer Society Cancer Facts and Figures 2025.  
2. American Lung Association. State of Lung Cancer 2024.

## AWARDS & RECOGNITIONS

### Healthcare Technology Report

Top 100 Healthcare Technology Companies of 2024

### Newsweek

World's Best Digital Health Companies of 2024

### Healthcare Technology Report

Top 25 Executives in Biotech 2024 & 2025

Scott Hutton, CEO Biodesix

### Denver Business Journal

Outstanding Women in Business 2025

Robin Harper Cowie, CFO Biodesix

### Denver Business Journal

Top Denver CFOs nominee 2024 & 2025

Robin Harper Cowie, CFO Biodesix

### ASCO 2024 Top 40 Under 40 in Cancer

Robbie Lunt, Senior Director of Marketing, Biodesix

### Top 5% individuals for citations on Doximity 2024

Dr. James Jett, Co-Chief Medical Officer, Biodesix

### Inc. Magazine

Best Workplaces 2024

### Denver Post

Top Workplaces 2025

## PRODUCT DEVELOPMENT PIPELINE

TEST	TYPE	INDICATION	UTILITY
Risk of Recurrence (ROR) & Molecular Residual Disease (MRD) Combination Test	Proteomic & Genomic	Lung and other solid tumor types	Likelihood of recurrence and recurrence monitoring
VeriStrat – immunotherapy	Proteomic	Lung and other solid tumor types with approved immunotherapy indications	Likelihood of response to standard of care immunotherapy and combination therapy
VeriStrat –prostate cancer	Proteomic	Castration-resistant metastatic prostate cancer	Likelihood of response to standard of care hormone therapy
Digital Diagnostics	Digital	Lung disease	Detection and diagnosis



FOR MORE  
INFORMATION

1.866.432.5930 | [biodesix.com](https://biodesix.com)  
919 W Dillon Rd, Louisville, CO 80027

©2025 Biodesix, Inc. All rights reserved. BioDSX0060 v1.0

